Drugs to
Watch in 2022

Potential blockbusters and innovators on the cusp.

These seven late-stage experimental treatments
stand to advance human health in 2022.

Download Drugs to Watch 2022

A glimpse at the future blockbusters and game-changing therapeutics on the verge of approval

This year’s report identifies seven experimental treatments worth keeping an eye on. It also looks at the regulatory and generic impact on the drug landscape of the future.

Download Drugs to Watch 2022

Share the list

Drugs to Watch 2022

These therapeutics are likely to achieve blockbuster status by 2026, per Clarivate analysis, and could transform treatment paradigms for the benefit of patients worldwide.

  1. Adagrasib
    Oncology – KRASG12C-positive NSCLC and CRC
  2. Faricimab
    Ophthalmology – Diabetic macular edema and wet age-related macular degeneration
  3. Lecanemab
    Neurology/psychiatric – Alzheimer’s disease
  4. Donanemab
    Neurology/psychiatric – Alzheimer’s disease
  5. Tezepelumab
    Respiratory – Severe asthma
  6. Tirzepatide
    Metabolic – Type 2 diabetes mellitus
  7. Vutrisiran
    Musculoskeletal – Transthyretin-mediated amyloidosis-related polyneuropathy

Explore Drugs to Watch 2022


Drugs to Watch identifies treatments entering the market that have potential to realize $1 billion USD annual sales within five years, based on interviews with therapy experts; Disease Landscape & Forecast reports; Cortellis™ sales data; and other industry sources.

Learn more

Key therapeutic development areas to watch

The drug innovation landscape is evolving, and many companies are developing platforms to address challenges in delivery and targeting across therapeutic areas.

Find out more about:

  • Cell and gene therapies
  • AI and machine learning discovery
  • RNA
  • Targeted cancer therapies

Download the report

COVID-19 vaccines and therapies

With more than 240 vaccines and 750+ treatments in development for COVID-19, pharmas continue their efforts to address the pandemic.

Explore COVID-19 vaccines and therapies


Truly differentiate your drug

Access our global intelligence, advanced analytics and global team of experts.

Speak to our team